-
1
-
-
34447298354
-
Pattern and prognostic factors in patients with malignant ascites: a retrospective study
-
Ayantunde A.A., Parsons S.L. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007, 18:945-949.
-
(2007)
Ann Oncol
, vol.18
, pp. 945-949
-
-
Ayantunde, A.A.1
Parsons, S.L.2
-
3
-
-
0033953879
-
Paracentesis-an effective method of symptom control in the palliative care setting?
-
McNamara P. Paracentesis-an effective method of symptom control in the palliative care setting?. Palliat Med 2000, 14:62-64.
-
(2000)
Palliat Med
, vol.14
, pp. 62-64
-
-
McNamara, P.1
-
4
-
-
0032144098
-
A survey of practice in management of malignant ascites
-
Lee C.W., Bociek G., Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage 1998, 16:96-101.
-
(1998)
J Pain Symptom Manage
, vol.16
, pp. 96-101
-
-
Lee, C.W.1
Bociek, G.2
Faught, W.3
-
6
-
-
0020602804
-
Peritoneovenous shunts in the management of malignant ascites
-
Souter R.G., Tarin D., Kettlewell M.G. Peritoneovenous shunts in the management of malignant ascites. Br J Surg 1983, 70:478-481.
-
(1983)
Br J Surg
, vol.70
, pp. 478-481
-
-
Souter, R.G.1
Tarin, D.2
Kettlewell, M.G.3
-
7
-
-
0020061153
-
Peritoneovenous shunt for palliation of malignant ascites
-
Qazi R., Savlov E.D. Peritoneovenous shunt for palliation of malignant ascites. Cancer 1982, 49:600-602.
-
(1982)
Cancer
, vol.49
, pp. 600-602
-
-
Qazi, R.1
Savlov, E.D.2
-
8
-
-
33644765785
-
Malignant ascites: systematic review and guideline for treatment
-
Becker G., Galandi D., Blum H.E. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006, 42:589-597.
-
(2006)
Eur J Cancer
, vol.42
, pp. 589-597
-
-
Becker, G.1
Galandi, D.2
Blum, H.E.3
-
9
-
-
0029901208
-
Malignant ascites: a 2-year review from a teaching hospital
-
Parsons S.L., Lang M.W., Steele R.J. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996, 22:237-239.
-
(1996)
Eur J Surg Oncol
, vol.22
, pp. 237-239
-
-
Parsons, S.L.1
Lang, M.W.2
Steele, R.J.3
-
10
-
-
0000655999
-
Use of nitrogen mustard in treatment of serous effusions of neoplastic origin
-
Weisberger A.S., Levine B., Storaasli J.P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955, 159:1704-1707.
-
(1955)
J Am Med Assoc
, vol.159
, pp. 1704-1707
-
-
Weisberger, A.S.1
Levine, B.2
Storaasli, J.P.3
-
11
-
-
0019972828
-
On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?
-
Appelqvist P., Silvo J., Salmela L., Kostiainen S. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed?. J Surg Oncol 1982, 20:238-242.
-
(1982)
J Surg Oncol
, vol.20
, pp. 238-242
-
-
Appelqvist, P.1
Silvo, J.2
Salmela, L.3
Kostiainen, S.4
-
12
-
-
0022616909
-
An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin
-
Ostrowski M.J. An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin. Cancer 1986, 57:721-727.
-
(1986)
Cancer
, vol.57
, pp. 721-727
-
-
Ostrowski, M.J.1
-
13
-
-
0028225234
-
Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin
-
Maiche A.G. Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Anticancer Drugs 1994, 5:305-308.
-
(1994)
Anticancer Drugs
, vol.5
, pp. 305-308
-
-
Maiche, A.G.1
-
14
-
-
0043245891
-
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites
-
xvi-xvii
-
Link K.H., Roitman M., Holtappels M., et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 2003, 12:865-872. xvi-xvii.
-
(2003)
Surg Oncol Clin N Am
, vol.12
, pp. 865-872
-
-
Link, K.H.1
Roitman, M.2
Holtappels, M.3
-
15
-
-
38749089075
-
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites
-
Oh S.Y., Kwon H.C., Lee S., et al. A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 2007, 37:930-935.
-
(2007)
Jpn J Clin Oncol
, vol.37
, pp. 930-935
-
-
Oh, S.Y.1
Kwon, H.C.2
Lee, S.3
-
16
-
-
0025689079
-
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer
-
Schilsky R.L., Choi K.E., Grayhack J., Grimmer D., Guarnieri C., Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 1990, 8:2054-2061.
-
(1990)
J Clin Oncol
, vol.8
, pp. 2054-2061
-
-
Schilsky, R.L.1
Choi, K.E.2
Grayhack, J.3
Grimmer, D.4
Guarnieri, C.5
Fullem, L.6
-
17
-
-
0026724629
-
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
-
Markman M., Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 1992, 118:547-550.
-
(1992)
J Cancer Res Clin Oncol
, vol.118
, pp. 547-550
-
-
Markman, M.1
Kelsen, D.2
-
18
-
-
37749046532
-
FP therapy for controlling malignant ascites in advanced pancreatic cancer patients
-
Yonemori K., Okusaka T., Ueno H., Morizane C., Takesako Y., Ikeda M. FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. Hepatogastroenterology 2007, 54:2383-2386.
-
(2007)
Hepatogastroenterology
, vol.54
, pp. 2383-2386
-
-
Yonemori, K.1
Okusaka, T.2
Ueno, H.3
Morizane, C.4
Takesako, Y.5
Ikeda, M.6
-
19
-
-
0027058837
-
Treatment of malignant peritoneal effusion in digestive and ovarian cancer
-
Gilly F.N., Carry P.Y., Brachet A., et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancer. Med Oncol Tumor Pharmacother 1992, 9:177-181.
-
(1992)
Med Oncol Tumor Pharmacother
, vol.9
, pp. 177-181
-
-
Gilly, F.N.1
Carry, P.Y.2
Brachet, A.3
-
20
-
-
0031263279
-
Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis
-
François Y., Grandclément E., Sayag-Beaujard A.C., et al. Intraperitoneal chemo-hyperthermia with mitomycin C in cancer of the stomach with peritoneal carcinosis. J Chir (Paris) 1997, 134:237-242.
-
(1997)
J Chir (Paris)
, vol.134
, pp. 237-242
-
-
François, Y.1
Grandclément, E.2
Sayag-Beaujard, A.C.3
-
21
-
-
33745992965
-
Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites
-
Garofalo A., Valle M., Garcia J., Sugarbaker P.H. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 2006, 32:682-685.
-
(2006)
Eur J Surg Oncol
, vol.32
, pp. 682-685
-
-
Garofalo, A.1
Valle, M.2
Garcia, J.3
Sugarbaker, P.H.4
-
22
-
-
0027369739
-
Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination
-
Kusano H., Miyashita K., Matsuo T., et al. Continuous hyperthermic peritoneal perfusion (CHPP) for prevention or treatment of peritoneal dissemination. Gan To Kagaku Ryoho 1993, 20:1622-1625.
-
(1993)
Gan To Kagaku Ryoho
, vol.20
, pp. 1622-1625
-
-
Kusano, H.1
Miyashita, K.2
Matsuo, T.3
-
23
-
-
0035489804
-
Prospective trial for the treatment of malignant peritoneal mesothelioma
-
Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., Geisinger K.R., Levine E.A. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001, 67:999-1003.
-
(2001)
Am Surg
, vol.67
, pp. 999-1003
-
-
Loggie, B.W.1
Fleming, R.A.2
McQuellon, R.P.3
Russell, G.B.4
Geisinger, K.R.5
Levine, E.A.6
-
24
-
-
0031034105
-
Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy
-
Loggie B.W., Perini M., Fleming R.A., Russell G.B., Geisinger K. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997, 63:137-143.
-
(1997)
Am Surg
, vol.63
, pp. 137-143
-
-
Loggie, B.W.1
Perini, M.2
Fleming, R.A.3
Russell, G.B.4
Geisinger, K.5
-
25
-
-
0034098315
-
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin
-
Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., Geisinger K.R. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000, 66:561-568.
-
(2000)
Am Surg
, vol.66
, pp. 561-568
-
-
Loggie, B.W.1
Fleming, R.A.2
McQuellon, R.P.3
Russell, G.B.4
Geisinger, K.R.5
-
26
-
-
50849099547
-
Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination
-
Esquivel J., Elias D., Baratti D., Kusamura S., Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 2008, 98:263-267.
-
(2008)
J Surg Oncol
, vol.98
, pp. 263-267
-
-
Esquivel, J.1
Elias, D.2
Baratti, D.3
Kusamura, S.4
Deraco, M.5
-
27
-
-
50849103061
-
Locoregional treatment of peritoneal carcinomatosis from gastric cancer
-
Bozzetti F., Yu W., Baratti D., Kusamura S., Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol 2008, 98:273-276.
-
(2008)
J Surg Oncol
, vol.98
, pp. 273-276
-
-
Bozzetti, F.1
Yu, W.2
Baratti, D.3
Kusamura, S.4
Deraco, M.5
-
28
-
-
50849119765
-
Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer
-
Helm C.W., Bristow R.E., Kusamura S., Baratti D., Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 2008, 98:283-290.
-
(2008)
J Surg Oncol
, vol.98
, pp. 283-290
-
-
Helm, C.W.1
Bristow, R.E.2
Kusamura, S.3
Baratti, D.4
Deraco, M.5
-
29
-
-
0024390361
-
Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer
-
Bezwoda W.R., Seymour L., Dansey R. Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 1989, 64:1029-1033.
-
(1989)
Cancer
, vol.64
, pp. 1029-1033
-
-
Bezwoda, W.R.1
Seymour, L.2
Dansey, R.3
-
30
-
-
0035742687
-
Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions A prospective pilot study
-
Sartori S., Nielsen I., Tassinari D., Trevisani L., Abbasciano V., Malacarne P. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions A prospective pilot study. Oncology 2001, 61:192-196.
-
(2001)
Oncology
, vol.61
, pp. 192-196
-
-
Sartori, S.1
Nielsen, I.2
Tassinari, D.3
Trevisani, L.4
Abbasciano, V.5
Malacarne, P.6
-
31
-
-
0027534622
-
Intraperitoneal interferon in the management of malignant ascites
-
Stuart G.C., Nation J.G., Snider D.D., Thunberg P. Intraperitoneal interferon in the management of malignant ascites. Cancer 1993, 71:2027-2030.
-
(1993)
Cancer
, vol.71
, pp. 2027-2030
-
-
Stuart, G.C.1
Nation, J.G.2
Snider, D.D.3
Thunberg, P.4
-
32
-
-
0028177909
-
Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients
-
B
-
Gebbia N., Mannino R., Di Dino A., et al. Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. Anticancer Res 1994, 14(2B):739-745.
-
(1994)
Anticancer Res
, vol.14
, Issue.2
, pp. 739-745
-
-
Gebbia, N.1
Mannino, R.2
Di Dino, A.3
-
33
-
-
0031030209
-
A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma
-
Hirte H.W., Miller D., Tonkin K., et al. A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 1997, 64:80-87.
-
(1997)
Gynecol Oncol
, vol.64
, pp. 80-87
-
-
Hirte, H.W.1
Miller, D.2
Tonkin, K.3
-
34
-
-
0020472233
-
Human leukocyte interferon therapy for advanced ovarian carcinoma
-
Einhorn N., Cantell K., Einhorn S., Strander H. Human leukocyte interferon therapy for advanced ovarian carcinoma. Am J Clin Oncol 1982, 5:167-172.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 167-172
-
-
Einhorn, N.1
Cantell, K.2
Einhorn, S.3
Strander, H.4
-
35
-
-
0025981202
-
Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites
-
Rath U., Kaufmann M., Schmid H., et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991, 27:121-125.
-
(1991)
Eur J Cancer
, vol.27
, pp. 121-125
-
-
Rath, U.1
Kaufmann, M.2
Schmid, H.3
-
36
-
-
0020507993
-
Intracavitary Corynebacterium parvum for treatment of malignant effusions
-
Currie J.L., Gall S., Weed J.C., Creasman W.T. Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol 1983, 16:6-14.
-
(1983)
Gynecol Oncol
, vol.16
, pp. 6-14
-
-
Currie, J.L.1
Gall, S.2
Weed, J.C.3
Creasman, W.T.4
-
37
-
-
0020627970
-
New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell mediated tumor cell destruction
-
Katano M., Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell mediated tumor cell destruction. Surgery 1983, 93:365-373.
-
(1983)
Surgery
, vol.93
, pp. 365-373
-
-
Katano, M.1
Torisu, M.2
-
38
-
-
0020541025
-
New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival
-
Torisu M., Katano M., Kimura Y., Itoh H., Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983, 93:357-364.
-
(1983)
Surgery
, vol.93
, pp. 357-364
-
-
Torisu, M.1
Katano, M.2
Kimura, Y.3
Itoh, H.4
Takesue, M.5
-
39
-
-
0347382821
-
Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+Th1 killer lymphocytes
-
Yamaguchi Y., Miyahara E., Ohshita A., et al. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+Th1 killer lymphocytes. Br J Cancer 2003, 89:1876-1884.
-
(2003)
Br J Cancer
, vol.89
, pp. 1876-1884
-
-
Yamaguchi, Y.1
Miyahara, E.2
Ohshita, A.3
-
40
-
-
0031797119
-
The past, the present and future of the OK-432 therapy for patients with malignant effusions
-
Katano M., Morisaki T. The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 1998, 18:3917-3925.
-
(1998)
Anticancer Res
, vol.18
, pp. 3917-3925
-
-
Katano, M.1
Morisaki, T.2
-
41
-
-
84856104578
-
-
http://clinicaltrials.gov/ct2/show/NCT00822809Zterm=ascites&rank=9.
-
-
-
-
42
-
-
0034069424
-
A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites
-
Mackey J.R., Wood L., Nabholtz J., et al. A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. J Pain Symptom Manage 2000, 19:193-199.
-
(2000)
J Pain Symptom Manage
, vol.19
, pp. 193-199
-
-
Mackey, J.R.1
Wood, L.2
Nabholtz, J.3
-
43
-
-
34447132202
-
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM×anti-CD3 antibody: a phase I/II study
-
Burges A., Wimberger P., Kumper C., et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM×anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007, 13:3899-3905.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 3899-3905
-
-
Burges, A.1
Wimberger, P.2
Kumper, C.3
-
44
-
-
42449141210
-
Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis
-
S, [abstr 2544]
-
Stroehlein M., Gruetzner K., Tarbichi A., et al. Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: a matched-pair analysis. J Clin Oncol 2006, 24(18S). [abstr 2544].
-
(2006)
J Clin Oncol
, vol.24
, Issue.18
-
-
Stroehlein, M.1
Gruetzner, K.2
Tarbichi, A.3
-
45
-
-
67549087235
-
Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM×anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients
-
[43rd June 02 Abs 5556]
-
Belau A., Pfisterer J., Wimberger P., et al. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM×anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. Am Soc Clin Oncol 2007, [43rd June 02 Abs 5556].
-
(2007)
Am Soc Clin Oncol
-
-
Belau, A.1
Pfisterer, J.2
Wimberger, P.3
-
46
-
-
52949107017
-
Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study
-
[43rd June 03 Abstr 5520]
-
Parsons S.L., Kutarska E., Koralewski P., et al. Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: results of a phase II/III study. Am Soc Clin Oncol 2007, [43rd June 03 Abstr 5520].
-
(2007)
Am Soc Clin Oncol
-
-
Parsons, S.L.1
Kutarska, E.2
Koralewski, P.3
-
47
-
-
52949109375
-
Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study
-
[abstr 102]
-
Parsons S.L., Muarwa P.X., Kolesnik O.O., et al. Treatment of epithelial cancer patients with malignant ascites using catumaxomab: results of the non-ovarian stratum of a phase II/III study. Proc Gastrointest Cancer Symp 2008, [abstr 102].
-
(2008)
Proc Gastrointest Cancer Symp
-
-
Parsons, S.L.1
Muarwa, P.X.2
Kolesnik, O.O.3
-
48
-
-
77953373836
-
Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab
-
[May 20 suppl; abstr 14006]
-
Ruf P., Jäger M., Volovat C., et al. Pharmacokinetics and in vivo stability of intraperitoneally administered therapeutic antibody catumaxomab. J Clin Oncol 2008, 26. [May 20 suppl; abstr 14006].
-
(2008)
J Clin Oncol
, vol.26
-
-
Ruf, P.1
Jäger, M.2
Volovat, C.3
-
49
-
-
63649133396
-
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab)(anti-EpCAM×anti-CD3): results of a phase I/II study
-
Sebastian M., Kiewe P., Schuette W., et al. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab)(anti-EpCAM×anti-CD3): results of a phase I/II study. J Immunother 2009, 32:195-202.
-
(2009)
J Immunother
, vol.32
, pp. 195-202
-
-
Sebastian, M.1
Kiewe, P.2
Schuette, W.3
-
50
-
-
34447642376
-
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM×anti-CD3): a phase I study
-
Sebastian M., Passlick B., Friccius-Quecke H., et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM×anti-CD3): a phase I study. Cancer Immunol Immunother 2007, 56:1637-1644.
-
(2007)
Cancer Immunol Immunother
, vol.56
, pp. 1637-1644
-
-
Sebastian, M.1
Passlick, B.2
Friccius-Quecke, H.3
-
51
-
-
84856103822
-
-
http://clinicaltrials.gov/ct2/show/NCT00822809Zterm=ascites&rank=9.
-
-
-
-
52
-
-
0034072645
-
Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo
-
Yukita A., Asano M., Okamoto T., Mizutani S., Suzuki H. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res 2000, 20:155-160.
-
(2000)
Anticancer Res
, vol.20
, pp. 155-160
-
-
Yukita, A.1
Asano, M.2
Okamoto, T.3
Mizutani, S.4
Suzuki, H.5
-
53
-
-
56449083159
-
The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report
-
Kesterson J.P., Mhawech-Fauceglia P., Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008, 111:527-529.
-
(2008)
Gynecol Oncol
, vol.111
, pp. 527-529
-
-
Kesterson, J.P.1
Mhawech-Fauceglia, P.2
Lele, S.3
-
54
-
-
56449083663
-
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
-
Hamilton C.A., Maxwell G.L., Chernofsky M.R., Bernstein S.A., Farley J.H., Rose G.S. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008, 111:530-532.
-
(2008)
Gynecol Oncol
, vol.111
, pp. 530-532
-
-
Hamilton, C.A.1
Maxwell, G.L.2
Chernofsky, M.R.3
Bernstein, S.A.4
Farley, J.H.5
Rose, G.S.6
-
55
-
-
33748475636
-
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
-
Numnum T.M., Rocconi R.P., Whitworth J., Barnes M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006, 102:425-428.
-
(2006)
Gynecol Oncol
, vol.102
, pp. 425-428
-
-
Numnum, T.M.1
Rocconi, R.P.2
Whitworth, J.3
Barnes, M.N.4
-
56
-
-
0033494157
-
Matrix metalloproteinase inhibitors: applications in oncology
-
Yip D., Ahmad A., Karapetis C.S., Hawkins C.A., Harper P.G. Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs 1999, 17:387-399.
-
(1999)
Invest New Drugs
, vol.17
, pp. 387-399
-
-
Yip, D.1
Ahmad, A.2
Karapetis, C.S.3
Hawkins, C.A.4
Harper, P.G.5
-
57
-
-
0031848158
-
Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
-
Beattie G.J., Smyth J.F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998, 4:1899-1902.
-
(1998)
Clin Cancer Res
, vol.4
, pp. 1899-1902
-
-
Beattie, G.J.1
Smyth, J.F.2
-
58
-
-
0031461180
-
Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites
-
Parsons S.L., Watson S.A., Steele R.J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997, 23:526-531.
-
(1997)
Eur J Surg Oncol
, vol.23
, pp. 526-531
-
-
Parsons, S.L.1
Watson, S.A.2
Steele, R.J.3
-
59
-
-
0032830056
-
Octreotide as an agent for the relief of malignant ascites in palliative care patients
-
Cairns W., Malone R. Octreotide as an agent for the relief of malignant ascites in palliative care patients. Palliat Med 1999, 13:429-430.
-
(1999)
Palliat Med
, vol.13
, pp. 429-430
-
-
Cairns, W.1
Malone, R.2
-
60
-
-
14644386870
-
The successful treatment of chylous effusions in malignant disease with octreotide
-
Mincher L., Evans J., Jenner M.W., Varney V.A. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol) 2005, 17:118-121.
-
(2005)
Clin Oncol (R Coll Radiol)
, vol.17
, pp. 118-121
-
-
Mincher, L.1
Evans, J.2
Jenner, M.W.3
Varney, V.A.4
-
61
-
-
84856081845
-
-
http://clinicaltrials.gov/ct2/show/NCT00182754Zintr=%22Octreotide%22&rank=40.
-
-
-
-
62
-
-
2942616642
-
Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au 198)
-
Dybicki J., Balchum O.J., Meneely G.R. Treatment of pleural and peritoneal effusion with intracavitary colloidal radiogold (Au 198). Arch Intern Med 1959, 104:802-815.
-
(1959)
Arch Intern Med
, vol.104
, pp. 802-815
-
-
Dybicki, J.1
Balchum, O.J.2
Meneely, G.R.3
-
63
-
-
2942577573
-
Malignant ascites: past, present, and future
-
Adam R.A., Adam Y.G. Malignant ascites: past, present, and future. J Am Coll Surg 2004, 198:999-1011.
-
(2004)
J Am Coll Surg
, vol.198
, pp. 999-1011
-
-
Adam, R.A.1
Adam, Y.G.2
-
64
-
-
0013942152
-
Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients
-
Ariel I.M., Oropeza R., Pack G.T. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 1966, 19:1096-1102.
-
(1966)
Cancer
, vol.19
, pp. 1096-1102
-
-
Ariel, I.M.1
Oropeza, R.2
Pack, G.T.3
-
65
-
-
2942565837
-
Radioactive colloidal chromic phosphate to control pleural effusion and ascites
-
Jacobs M.L. Radioactive colloidal chromic phosphate to control pleural effusion and ascites. J Am Med Assoc 1958, 166:597-599.
-
(1958)
J Am Med Assoc
, vol.166
, pp. 597-599
-
-
Jacobs, M.L.1
-
66
-
-
0007106163
-
Summary of ten years of the use of radioactive colloids in intracavitary therapy
-
Card R.Y., Cole D.R., Henschke U.K. Summary of ten years of the use of radioactive colloids in intracavitary therapy. J Nucl Med 1960, 1:195-198.
-
(1960)
J Nucl Med
, vol.1
, pp. 195-198
-
-
Card, R.Y.1
Cole, D.R.2
Henschke, U.K.3
-
67
-
-
0016712161
-
Loculation as a contraindication intracavitary 32P-chromic phosphate therapy
-
Taylor A., Baily N.A., Halpern S.E., Ashburn W.L. Loculation as a contraindication intracavitary 32P-chromic phosphate therapy. J Nucl Med 1975, 16:318-319.
-
(1975)
J Nucl Med
, vol.16
, pp. 318-319
-
-
Taylor, A.1
Baily, N.A.2
Halpern, S.E.3
Ashburn, W.L.4
-
68
-
-
50849130946
-
The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus
-
September
-
Baratti D., Kusamura S., Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus. J Surg Oncol 2008, 98(September (4)):258-262.
-
(2008)
J Surg Oncol
, vol.98
, Issue.4
, pp. 258-262
-
-
Baratti, D.1
Kusamura, S.2
Deraco, M.3
-
69
-
-
84856081843
-
-
http://clinicaltrials.gov/ct2/show/NCT00796861Zterm=ascites&rank=8.
-
-
-
-
70
-
-
84856121341
-
-
http://clinicaltrials.gov/ct2/show/NCT00826150Zterm=ascites&rank=56.
-
-
-
-
71
-
-
84856104576
-
-
http://clinicaltrials.gov/ct2/show/NCT00796861.
-
-
-
-
72
-
-
33646409016
-
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis
-
Hahn S.M., Fraker D.L., Mick R., et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006, 12:2517-2525.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 2517-2525
-
-
Hahn, S.M.1
Fraker, D.L.2
Mick, R.3
-
73
-
-
0000925409
-
Intraperitoneal photodynamic therapy shows efficacy in phase I trial
-
Sindelar W., Sullivan F., Abraham E., et al. Intraperitoneal photodynamic therapy shows efficacy in phase I trial. Proc Am Soc Clin Oncol 2005, 14:447.
-
(2005)
Proc Am Soc Clin Oncol
, vol.14
, pp. 447
-
-
Sindelar, W.1
Sullivan, F.2
Abraham, E.3
-
74
-
-
33749663630
-
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR
-
October
-
Pfisterer J., du Bois A., Sehouli J., et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006, 17(October (10)):1568-1577.
-
(2006)
Ann Oncol
, vol.17
, Issue.10
, pp. 1568-1577
-
-
Pfisterer, J.1
du Bois, A.2
Sehouli, J.3
|